Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: April 18, 2024
Abstract
Cancer,
a
complex
and
multifactorial
disease,
presents
significant
challenge
to
global
health.
Despite
advances
in
surgical,
radiotherapeutic
immunological
approaches,
which
have
improved
cancer
treatment
outcomes,
drug
therapy
continues
serve
as
key
therapeutic
strategy.
However,
the
clinical
efficacy
of
is
often
constrained
by
resistance
severe
toxic
side
effects,
thus
there
remains
critical
need
develop
novel
therapeutics.
One
promising
strategy
that
has
received
widespread
attention
recent
years
repurposing:
identification
new
applications
for
existing,
clinically
approved
drugs.
Drug
repurposing
possesses
several
inherent
advantages
context
since
repurposed
drugs
are
typically
cost-effective,
proven
be
safe,
can
significantly
expedite
development
process
due
their
already
established
safety
profiles.
In
light
this,
present
review
offers
comprehensive
overview
various
methods
employed
repurposing,
specifically
focusing
on
treat
cancer.
We
describe
antitumor
properties
candidate
drugs,
discuss
detail
how
they
target
both
hallmarks
tumor
cells
surrounding
microenvironment.
addition,
we
examine
innovative
integrating
with
nanotechnology
enhance
topical
delivery.
also
emphasize
role
play
when
used
part
combination
regimen.
To
conclude,
outline
challenges
associated
consider
future
prospects
these
transitioning
into
application.
Journal of Hematology & Oncology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: June 28, 2022
Abstract
Cancer
is
one
of
the
leading
causes
death
worldwide,
and
factors
responsible
for
its
progression
need
to
be
elucidated.
Exosomes
are
structures
with
an
average
size
100
nm
that
can
transport
proteins,
lipids,
nucleic
acids.
This
review
focuses
on
role
exosomes
in
cancer
therapy.
We
discuss
how
able
modulate
components
tumor
microenvironment
influence
proliferation
migration
rates
cells.
also
highlight
that,
depending
their
cargo,
suppress
or
promote
cell
enhance
reduce
response
radio-
chemo-therapies.
In
addition,
we
describe
trigger
chronic
inflammation
lead
immune
evasion
by
focusing
ability
transfer
non-coding
RNAs
between
cells
other
molecular
signaling
pathways
such
as
PTEN
PI3K/Akt
cancer.
Subsequently,
use
carriers
anti-tumor
agents
genetic
tools
control
progression.
then
tumor-derived
carcinogenesis.
Finally,
devote
a
section
study
diagnostic
prognostic
clinical
courses
important
treatment
patients.
provides
comprehensive
understanding
therapy,
therapeutic
value
remodeling
microenvironment.
Graphical
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: July 29, 2022
Abstract
Radiotherapy
(RT)
is
delivered
for
purposes
of
local
control,
but
can
also
exert
systemic
effect
on
remote
and
non-irradiated
tumor
deposits,
which
called
abscopal
effect.
The
view
RT
as
a
simple
treatment
has
dramatically
changed
in
recent
years,
it
now
widely
accepted
that
provoke
immune
response
gives
strong
rationale
the
combination
immunotherapy
(iRT).
Nevertheless,
several
points
remain
to
be
addressed
such
interaction
system,
identification
best
schedules
with
(IO),
expansion
mechanism
amplify
iRT.
To
answer
these
crucial
questions,
we
roundly
summarize
underlying
showing
whole
landscape
clinical
trials
attempt
identify
In
consideration
rarity
effect,
propose
occurrence
induced
by
radiation
promoted
100%
molecular
genetic
level.
Furthermore,
“radscopal
effect”
refers
using
low-dose
reprogram
microenvironment
may
overcome
resistance
Taken
together,
could
regarded
trigger
antitumor
response,
help
IO
used
radical
added
into
current
standard
regimen
patients
metastatic
cancer.
Frontiers in Chemistry,
Journal Year:
2021,
Volume and Issue:
9
Published: Aug. 2, 2021
Photodynamic
therapy
(PDT)
has
been
used
as
an
anti-tumor
treatment
method
for
a
long
time
and
photosensitizers
(PS)
can
be
in
various
types
of
tumors.
Originally,
light
is
effective
tool
that
the
diseases
ages.
The
effects
combination
specific
dyes
with
illumination
was
demonstrated
at
beginning
20th
century
novel
PDT
approaches
have
developed
ever
since.
Main
strategies
current
studies
are
to
reduce
off-target
improve
pharmacokinetic
properties.
Given
high
interest
vast
literature
about
topic,
approval
first
drug/device
by
FDA
should
come
no
surprise.
consists
two
stages
treatment,
combining
energy
PS
order
destruct
tumor
cells
after
activation
light.
In
general,
fewer
side
toxicity
than
chemotherapy
and/or
radiotherapy.
addition
purpose
several
PSs
diagnostic
purposes
Such
called
photodynamic
diagnosis
(PDD).
this
Review,
we
provide
general
overview
clinical
applications
cancer,
including
therapeutic
approaches.
Assessment
efficacy
clinic
will
discussed,
since
identifying
predictors
determine
response
crucial.
addition,
examples
tumors
discussed.
Furthermore,
other
modalities
such
chemotherapy,
radiotherapy,
surgery
immunotherapy
emphasized,
seem
promising
terms
enhancing
effectiveness
against
tumor.
treatments
may
yield
better
results
single
treatments.
Moreover,
utilization
lower
doses
setting
cause
less
therapy.
A
understanding
well
optimization
complex
multimodal
expand
PDT.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2021,
Volume and Issue:
40(1)
Published: July 24, 2021
As
competitive
HMG-CoA
reductase
(HMGCR)
inhibitors,
statins
not
only
reduce
cholesterol
and
improve
cardiovascular
risk,
but
also
exhibit
pleiotropic
effects
that
are
independent
of
their
lipid-lowering
effects.
Among
them,
the
anti-cancer
properties
have
attracted
much
attention
indicated
potential
as
repurposed
drugs
for
treatment
cancer.
A
large
number
clinical
epidemiological
studies
described
anticancer
statins,
evidence
effectiveness
is
inconsistent.
It
may
be
certain
molecular
subtypes
cancer
more
vulnerable
to
statin
therapy
than
others.
Whether
still
an
active
area
research.
Statins
appear
enhance
efficacy
address
shortcomings
associated
with
conventional
treatments,
suggesting
should
considered
in
context
combined
therapies
Here,
we
present
a
comprehensive
review
treatments.
We
discuss
current
understanding
mechanisms
underlying
on
different
malignancies.
provide
recommendations
design
future
well-designed
trials
statins.
Drug Resistance Updates,
Journal Year:
2021,
Volume and Issue:
59, P. 100796 - 100796
Published: Dec. 1, 2021
Driver
mutations
promote
initiation
and
progression
of
cancer.
Pharmacological
treatment
can
inhibit
the
action
mutant
protein;
however,
drug
resistance
almost
invariably
emerges.
Multiple
studies
revealed
that
cancer
is
based
upon
a
plethora
distinct
mechanisms.
Drug
occur
in
same
protein
or
different
proteins;
as
well
pathway
parallel
pathways,
bypassing
intercepted
signaling.
The
dilemma
clinical
oncologist
facing
not
all
genomic
alterations
tumor
microenvironment
facilitate
cell
proliferation
are
known,
neither
likely
to
metastasis.
For
example,
common
KRas
Frontiers in Immunology,
Journal Year:
2020,
Volume and Issue:
11
Published: Oct. 6, 2020
Ovarian
cancer
is
the
most
lethal
gynecologic
malignancy.
Surgery
and
chemotherapy
are
primary
treatments
for
ovarian
cancer;
however,
patients
often
succumb
to
recurrence
with
chemotherapeutic
resistance
within
several
years
after
initial
treatment.
In
past
two
decades,
immunotherapy
has
rapidly
developed
revolutionize
treatment
of
various
types
cancer.
Despite
fact
that
response
rates
among
remain
modest,
immune
checkpoint
inhibitors
(ICIs),
chimeric
antigen
receptor
(CAR)-
TCR-engineered
T
cells
developing.
Therapeutic
efficiency
could
be
improved
significantly
if
included
as
an
adjuvant
therapy,
in
combination
chemotherapy,
radiation
anti-angiogenesis
drugs,
poly
ADP
ribose
polymerase
(PARPi).
Newly
technologies
identify
therapeutic
targets,
predict
efficacy,
screen
potential
provide
neoadjuvant
immunotherapy,
utilize
nanomedicine
technology
new
opportunities
have
prolong
patient
survival.
However,
important
issues
may
hinder
efficacy
such
approaches,
including
hyperprogressive
disease
(HPD),
immunotherapy-resistance,
toxicity
treatments,
neurotoxicity,
must
taken
into
account
addressed
these
therapies
effective.
Journal of Biomedical Science,
Journal Year:
2022,
Volume and Issue:
29(1)
Published: Oct. 17, 2022
Abstract
Tumor
microenvironment
(TME)
is
a
specialized
ecosystem
of
host
components,
designed
by
tumor
cells
for
successful
development
and
metastasis
tumor.
With
the
advent
3D
culture
advanced
bioinformatic
methodologies,
it
now
possible
to
study
TME’s
individual
components
their
interplay
at
higher
resolution.
Deeper
understanding
immune
cell’s
diversity,
stromal
constituents,
repertoire
profiling,
neoantigen
prediction
TMEs
has
provided
opportunity
explore
spatial
temporal
regulation
therapeutic
interventions.
The
variation
TME
composition
among
patients
plays
an
important
role
in
determining
responders
non-responders
towards
cancer
immunotherapy.
Therefore,
there
could
be
possibility
reprogramming
overcome
widely
prevailing
issue
immunotherapeutic
resistance.
focus
present
review
understand
complexity
comprehending
future
perspective
its
as
potential
targets.
later
part
describes
sophisticated
models
emerging
valuable
means
extensive
account
tools
profile
predict
neoantigens.
Overall,
this
provides
comprehensive
current
knowledge
available
target
TME.
Frontiers in Immunology,
Journal Year:
2021,
Volume and Issue:
12
Published: July 19, 2021
Immunotherapy
aiming
at
suppressing
tumor
development
by
relying
on
modifying
or
strengthening
the
immune
system
prevails
among
cancer
treatments
and
points
out
a
new
direction
for
therapy.
B7
homolog
3
protein
(B7-H3,
also
known
as
CD276),
newly
identified
immunoregulatory
member
of
family,
is
an
attractive
promising
target
immunotherapy
because
it
overexpressed
in
tissues
while
showing
limited
expression
normal
participating
microenvironment
(TME)
shaping
development.
Thus
far,
numerous
B7-H3-based
strategies
have
demonstrated
potent
antitumor
activity
acceptable
safety
profiles
preclinical
models.
Herein,
we
present
biological
function
B7-H3
distinct
cells,
well
B7-H3-mediated
signal
pathways
cells
strategies.
This
review
provides
comprehensive
overview
that
encompasses
B7-H3’s
role
TME
to
its
potential
immunotherapy.
Exploration,
Journal Year:
2022,
Volume and Issue:
2(2)
Published: March 7, 2022
Chemodynamic
therapy
(CDT)
has
emerged
to
be
a
frontrunner
amongst
reactive
oxygen
species-based
cancer
treatment
modalities.
CDT
utilizes
endogenous
H